An observational study in Chemotherapy-Induced Amenorrhea, sponsored by University Hospital, Lille. Recruiting at 1 site in France. Open to female participants aged 25 Years to 35 Years. Per ClinicalTrials.gov, last updated 2025-12-26.
Sponsored by University Hospital, Lille · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Chemotherapy for cancer, due to its gonadotoxicity, can lead to impaired female fertility, resulting in the occurrence of transient or prolonged chemo-induced amenorrhea (CIA). According to recent data from the National Cancer Institute, 11.9% of women under the age of 40 diagnosed with cancer have been offered a fertility evaluation within five years of diagnosis. Predicting the risk and especially the duration of the CIA remains difficult. Known factors predicting a rapid return of menstruation are a young age at diagnosis, a low gonadotoxic treatment (absence of alkylating agents) and a high pre-chemotherapy blood level of AMH reflecting a large pool of growing follicles. A body mass index (BMI) ≥ 25 kg / m² could also be a positive predictor, but this remains debated.
The objective of this project is to assess the impact of metabolism and energy reserves, physical activity and the chronotype on the recovery of ovarian function in patients with breast cancer who have developed CIA
80 studies on the registry are indexed under Amenorrhea; 17 are open to participants now.
This study's planned enrollment of 50 is below the median of 85 across 26 observational studies indexed under Amenorrhea.
Browse Amenorrhea studies →University Hospital, Lille is the lead sponsor of 631 studies on the registry; 142 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Women with a chemotherapy-induced (CIA) amenorrhea who asked for post-cancer fertility follow-up at the University Hospital of Lille, France.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Concentration of IL-6 levels at the end of chemotherapy
Study the association between the IL-6 blood levels (in pg/ml) at the end of chemotherapy and the menstrual period return state ( before or after 6 months)
Time frame: 1 year
Correlation between blood metabolic markers (Leptin, Insulin, Ghrelin) and menstrual period return state
Leptin concentration in ng/ml; insulin concentration in mUI/L; ghrelin concentrations in pg/ml
Time frame: 1 year
Correlation between physical activity score at the end of chemotherapy and menstrual period return state
Physical activity score expressed in arbitrary units
Time frame: 1 year
Correlation between chronotype score at the end of chemotherapy and menstrual period return state
chronotype score expressed in arbitrary units
Time frame: 1 year
Correlation between the BMI at the end of chemotherapy and menstrual period return state
weight and height will be combined to report BMI in kg/m2
Time frame: 1 year
Correlation between Blood metabolic markers (Leptin, Insulin, Ghrelin) assessed at 3 months and menstrual period return state
Leptin concentration in ng/ml, Insulin concentration in mUI/L, Ghrelin concentration in pg/ml
Time frame: 9 months
Correlation between the Physical activity Score at 3 months and the menstrual period return state (between 3 to 12 months)
Physical activity score expressed in arbitrary units
Time frame: 9 months
Correlation between the BMI assessed at 3 months and the menstrual period return state (between 3 to 12 months)
weight and height assessed at 3 months will be combined to report BMI in kg/m2
Time frame: 9 months
Evolution of the blood concentration of insulin over the follow-up period (12 months)
insulin concentrations expressed in mUI/L
Time frame: 1 year
Correlation between the Chronotype Score at 3 months and the menstrual period return state (between 3 to 12 months)
chronotype score expressed in arbitrary units
Time frame: 9 months
Evolution of the blood concentration of Leptin over the follow-up period (12 months)
leptin concentrations expressed in ng/ml
Time frame: 1 year
Evolution of the blood concentration of Ghrelin over the follow-up period (12 months)
ghrelin concentrations expressed in pg/ml
Time frame: 1 year
Started Feb 2022 (actual). Primary completion is estimated for Jun 2026, 52 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.